Pfizer delays advertising Exubera

Share this article:
Pfizer will hold off on advertising Exubera to consumers for one year while it focuses on education. Pfizer CEO Hank McKinnell told attendees at a June Goldman Sachs Global Healthcare Conference that the company would focus on educating professionals on the inhaled insulin, doubling the length of its 6-month moratorium on DTC ads for new drugs. McKinnell's remarks were first reported in The Pink Sheet.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.